Investing.com – Acer Therapeutics (NASDAQ:) reported on Monday its third quarter that beat analysts’ forecasts and revenue that was in line with expectations.
Acer Therapeutics announced earnings per share of $-0.310 on revenue of $0.00. Analysts polled by Investing.com were expecting EPS of $-0.755 on revenue of $0.00.
Shares of Acer Therapeutics are down 30% year-to-date, still down 68.17% from the 52-week high of $3.77 set on April 4.
Acer Therapeutics follows another big earner in the Healthcare sector this month
Acer Therapeutics’ report follows J&J’s earnings beat on Oct. 18, which reported EPS of $2.55 on revenue of $23.79B, compared to EPS forecasts of $2.48 on revenue of $23.36B.
Eli Lilly beat expectations on Nov. 1 with third-quarter EPS of $1.98 on revenue of $6.94B, compared to the forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar